Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin's Lymphoma

American Society of Clinical Oncology (ASCO) - Tập 23 Số 30 - Trang 7614-7620 - 2005
William G. Martin1, Kay M. Ristow1, Thomas M. Habermann1, Joseph P. Colgan1, Thomas E. Witzig1, Stephen M. Ansell1
1From the Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN

Tóm tắt

Purpose Bleomycin pulmonary toxicity (BPT) has been well described in Hodgkin's lymphoma (HL) patients treated with bleomycin-containing chemotherapy regimens. The influence of this pulmonary complication, along with the omission of bleomycin from further chemotherapy, on overall survival (OS) and progression-free survival (PFS) in HL remains unclear. We reviewed our experience with BPT in HL to better delineate outcome and appropriate treatment in these patients. Patients and Methods One hundred forty-one patients who were treated with bleomycin-containing chemotherapy for newly diagnosed HL between January 1986 and February 2003 were eligible for this retrospective review. BPT was defined by the presence of pulmonary symptoms, bilateral interstitial infiltrates, and no evidence of an infectious etiology. Results BPT was observed in 18% of patients. Increasing age, doxorubicin, bleomycin, vinblastine, and dacarbazine as initial therapy, and granulocyte colony-stimulating factor use were associated with the development of BPT. Patients with BPT had a median 5-year OS rate of 63% v 90% (P = .001) in unaffected patients. The mortality rate from BPT was 4.2% in all patients and 24% in patients who developed the pulmonary syndrome. BPT incidence and mortality were highest in patients older than 40 years. The omission of bleomycin had no impact on obtaining a complete remission, PFS, or OS. Conclusion BPT results in a significant decrease in 5-year OS in patients who are treated for HL. Age ≥ 40 years seems to add substantially to the risk. In patients who do not die from acute pulmonary toxicity, both OS and PFS seem equal, despite the omission of bleomycin.

Từ khóa


Tài liệu tham khảo

10.1200/JCO.1986.4.9.1295

10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7

10.1056/NEJM199211193272102

10.1200/JCO.2003.12.086

10.1200/JCO.1997.15.4.1638

10.1016/0014-2964(72)90045-X

10.1002/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N

10.1056/NEJMoa022473

10.1200/jco.2002.20.3.630

10.1378/chest.120.2.617

10.1001/jama.1980.03300300025019

10.1056/NEJM199811193392104

10.1002/1097-0142(1967)20:5<891::AID-CNCR2820200550>3.0.CO;2-V

10.1200/jco.2004.22.14_suppl.1532

Matthews JH: Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: Possible synergy. Lancet 342:988,1993,

10.1002/1097-0142(197405)33:5<1230::AID-CNCR2820330507>3.0.CO;2-C

10.1097/01.CCM.0000050453.28177.33

10.1378/chest.111.3.657

Bastion Y, Coiffier B: Pulmonary toxicity of bleomycin: Is G-CSF a risk factor? Lancet 344:474,1994,

Bastion Y, Reyes F, Bosly A, et al: Possible toxicity with the association of G-CSF and bleomycin. Lancet 343:1221,1994-1222,

10.1016/S0140-6736(94)91076-6

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 23 Số 30

7614-7620

Thông tin tác giả